Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) reported Q3 CY2025 results topping the market’s revenue expectations , with sales up 53.6% year on year to $227.8 million. The company’s full-year revenue guidance of $863.5 million at the midpoint came in 1.8% above analysts’ estimates. Its non-GAAP profit of $2.04 per share was 15.2% above analysts’ consensus estimates.
Is now the time to buy ANIP? Find out in our full research report (it’s free for active Edge members).
-
Revenue: $227.8 million vs analyst estimates of $214.1 million (53.6% year-on-year growth, 6.4% beat)
-
Adjusted EPS: $2.04 vs analyst estimates of $1.77 (15.2% beat)
-
Adjusted EBITDA: $59.6 million vs analyst estimates of $55.24 million (26.2% margin, 7.9% beat)
-
The company lifted its revenue guidance for the full year to $863.5 million at the midpoint from $830.5 million, a 4% increase
-
Management raised its full-year Adjusted EPS guidance to $7.51 at the midpoint, a 4.7% increase
-
EBITDA guidance for the full year is $224.5 million at the midpoint, above analyst estimates of $221.9 million
-
Operating Margin: 15.9%, up from -13.8% in the same quarter last year
-
Market Capitalization: $1.87 billion
ANI Pharmaceuticals delivered a third quarter marked by substantial year-over-year growth, with management attributing performance to strong momentum across its Rare Disease and Generics segments. CEO Nikhil Lalwani highlighted that Cortrophin Gel nearly doubled net revenue compared to the prior year and that a significant partner generic launch further bolstered results. The company also saw record new patient starts and expanded prescriber adoption, especially in new therapeutic areas such as pulmonology and ophthalmology. Lalwani pointed to “the strong underlying demand and the addressable patient populations across key indications” as core drivers behind the quarter’s success.
Looking ahead, ANI Pharmaceuticals’ updated guidance reflects management’s expectation of continued growth driven by its Rare Disease portfolio, particularly Cortrophin Gel. The company is focused on expanding clinical evidence, investing in commercial initiatives, and improving patient convenience, with Lalwani stating, “We remain confident in the strong multiyear growth trajectory of Cortrophin.” Management also acknowledged ongoing efforts to support ILUVIEN’s adoption and hinted at future business development opportunities to expand the Rare Disease segment. CFO Stephen Carey indicated that revised guidance assumes continued strong performance in Rare Disease and Generics, while ILUVIEN is expected to recover in the longer term.
Management credited third quarter outperformance to robust demand for Cortrophin Gel, new product launches in Generics, and successful commercial expansion in specialty areas.
-
Cortrophin Gel adoption acceleration: Management reported that expanded sales efforts led to record numbers of new patient starts and cases across specialties like rheumatology, nephrology, neurology, pulmonology, and ophthalmology. The prefilled syringe, launched earlier in the year, simplified administration and rapidly became a preferred option, accounting for nearly 70% of new cases initiated.
-
Growth in underpenetrated indications: Cortrophin Gel’s unique label for acute gouty arthritis and increased penetration in areas such as pulmonology and ophthalmology contributed to broader prescriber uptake, with CEO Nikhil Lalwani noting that roughly half of prescribers were previously unfamiliar with ACTH therapies.
-
Generics segment upside: A partnered generic product launch provided an unexpected boost to the Generics business, demonstrating ANI’s ability to leverage its R&D and business development capabilities. Management expects this momentum to moderate as competition increases in subsequent quarters, but noted ongoing pursuit of similar opportunities.
-
ILUVIEN challenges and reset: Sales of ILUVIEN, used for retinal diseases, were impacted by reduced Medicare patient access and inventory dynamics. Management described 2025 as a reset year for ILUVIEN, but outlined plans for renewed growth in 2026 via expanded peer education and market access pathways.
-
Increased investment in clinical evidence: The company is conducting a Phase IV trial for Cortrophin Gel in acute gouty arthritis and publishing preclinical data in additional indications. Management believes this evidence will support broader physician adoption and potential inclusion in treatment guidelines.
Management expects further growth to be driven by continued investment in Rare Disease products, product innovation, and expansion of market access initiatives, while monitoring headwinds in certain product lines.
-
Cortrophin Gel multiyear growth: Management believes the largest opportunity remains in expanding Cortrophin Gel’s use across underpenetrated indications. Ongoing clinical studies and the prefilled syringe are anticipated to unlock additional demand in specialties like gout, nephrology, and ophthalmology.
-
Generics pipeline and competition: While the Generics segment benefited from a one-time partnered product launch, management expects competitive entrants to pressure future growth. Nevertheless, ANI’s U.S.-based manufacturing and business development efforts aim to source new opportunities and maintain foundational support for Rare Disease investments.
-
ILUVIEN recovery efforts: The company considers 2025 a reset year for ILUVIEN, with expectations for renewed growth in 2026. Strategies include a strengthened ophthalmology sales team, expanded education initiatives, and efforts to resolve market access gaps—particularly for Medicare patients.
In the quarters ahead, the StockStory team will monitor (1) the pace of Cortrophin Gel adoption in new specialties and the impact of ongoing clinical trials, (2) efforts to stabilize and grow ILUVIEN sales as education and market access initiatives ramp up, and (3) the launch and competitive dynamics of future generics. Progress in business development and the potential for additional Rare Disease asset acquisitions will also be key signposts.
ANI Pharmaceuticals currently trades at $91.35, up from $90.34 just before the earnings. Is the company at an inflection point that warrants a buy or sell? See for yourself in our full research report (it’s free for active Edge members).
Fresh US-China trade tensions just tanked stocks—but strong bank earnings are fueling a sharp rebound. Don’t miss the bounce.
Don’t let fear keep you from great opportunities and take a look at Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.